DNIB Unwind, Inc.
(Other OTC/NBB : BIND)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.43%688.872.6%$679.29m
MRNAModerna, Inc. 0.15%118.250.0%$616.94m
AMGNAmgen, Inc. -1.32%225.401.4%$605.62m
BIIBBiogen, Inc. 1.03%267.001.8%$554.62m
GILDGilead Sciences, Inc. -2.19%61.691.0%$514.54m
VRTXVertex Pharmaceuticals, Inc. -1.11%289.541.9%$401.56m
ILMNIllumina, Inc. -1.56%190.793.2%$338.76m
SNSSSunesis Pharmaceuticals, Inc. 4.40%4.270.7%$298.49m
SAVACassava Sciences, Inc. -2.90%41.820.0%$189.63m
BNTXBioNTech SE 0.96%134.880.0%$112.19m
NVAXNovavax, Inc. -1.99%18.2075.6%$84.03m
BMRNBioMarin Pharmaceutical, Inc. -0.34%84.774.2%$82.56m
NRBONeuroBo Pharmaceuticals, Inc. 9.35%13.690.0%$78.90m
PRTAProthena Corp. Plc 1.95%60.6313.8%$78.20m
CRSPCRISPR Therapeutics AG 1.33%65.350.6%$76.10m

Company Profile

They are a clinical-stage nanomedicine platform company developing Accurinsâ„¢, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.